KSAT 12: San Antonio cancer center bracing for possible impact of drug shortage crisis
June 7, 2023
Mark Bonnen, MD, chair, Radiation Oncology, UT Health San Antonio Mays Cancer Center, was interviewed for this news story. Read More
Category
June 7, 2023
Mark Bonnen, MD, chair, Radiation Oncology, UT Health San Antonio Mays Cancer Center, was interviewed for this news story. Read More
June 6, 2023
The Mays Cancer Center at the University of Texas Health Science Center at San Antonio has ranked fourth in the nation for clinical trial enrollments among over a thousand institutions that are members of SWOG Cancer Research Network, formerly known as the Southwestern Oncology Group. SWOG is an organization supported by the National Cancer […]
May 24, 2023
Andrew Brenner, MD, Neurosurgery, and William Kelly, MD, Hematology & Oncology, both of the UT Health San Antonio Mays Cancer Center, were mentioned in this story via the word ‘conducted,’ which links to the university’s press release about the Mays Cancer Center conducting the only clinical trial in America of a specific drug combination for […]
May 23, 2023
An improvement in 6-month progression-free survival warrants additional study in a larger trial, researchers said. The Mays Cancer Center at The University of Texas Health Science Center at San Antonio recently conducted a clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma (GBM). The Mays Cancer Center, one of the four National Cancer […]
May 23, 2023
Kate Lathrop, MD, Hematology & Oncology, UT Health San Antonio Mays Cancer Center, was interviewed for this news segment. Watch Now
May 17, 2023
Glioblastoma-impacted mice lived longer when treated with combination of molecule drug and chemotherapy agent Glioblastoma (GBM), a highly devastating brain tumor, has long posed challenges as effective treatments have remained elusive. Despite responding initially to treatment, GBM patients often experience therapy resistance leading to low long-term survival rates, with only 7.2% of patients surviving beyond […]